Sjællands Universitetshospital_Roskilde
Roskilde 4000
1 studies enrolling now · 11 studies all time
What they study most
COVID-19 Pneumonia, Cardiovascular Risk, Chronic Kidney Disease, Chronic Lymphocytic Leukemia, Diabetic Macular Edema, Early Alzheimer's Disease, Early Alzheimer´s Disease, Heart Failure, KRAS G12C Lung Cancer, Neovascular Age-related Macular Degeneration, Non-Cystic Fibrosis Bronchiectasis, Non-Small Cell Lung Cancer
Studies at this site
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting now
- A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
- A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
- A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer — Completed
- A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) — Completed
- A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema — Completed
- Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) — Completed
- A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) — Completed
- Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis — Completed
- A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia — Completed